---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-308409"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-07-20T12:30:05+00:00"
generated_at: "2026-07-20T12:35:04.561861+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular reports positive 2-year Phase 2b data for 4D-150 in wet AMD; 78% treatment burden reduction

## Summary
- Overall cohort: 78% reduction in treatment burden (2.7 mean supplemental injections vs 12.0 projected for aflibercept Q8W).
- Recently diagnosed subgroup: 87% reduction (1.6 mean supplemental injections vs 12.0).
- Dose response maintained in favor of Phase 3 dose (3E10 vg/eye) over 2 years.
- Safety: 2.8% (2/71) had transient mild IOI within first 28 weeks; no new inflammation with up to 4+ years follow-up.
- No 4D-150-related hypotony, endophthalmitis, vasculitis, or choroidal effusions observed.

## SEC filing metadata
- accession: 0001193125-26-308409
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-07-20T12:30:05+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/0001193125-26-308409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-308409
- JSON: https://secwatch.observer/filing/0001193125-26-308409.json
- Plain text: https://secwatch.observer/filing/0001193125-26-308409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.